Researchclopedia

Research Researchers Institutions Topics Submit About

Command Palette

Search for a command to run...

Researchclopedia

Research Researchers Institutions About

© 2026 Researchclopedia. Powered by OpenAlex under CC0 license.

Arndt Vogel | Researchclopedia

Back to researchers

Arndt Vogel

Ontario Institute for Cancer Research ORCID

769

Works

37,860

Citations

83

h-index

311

i10-index

Research Topics

Hepatocellular Carcinoma Treatment and Prognosis Cholangiocarcinoma and Gallbladder Cancer Studies Pancreatic and Hepatic Oncology Research

Affiliations

Ontario Institute for Cancer Research2025–2025

Goethe University Frankfurt2017–2017

Oslo University Hospital2024–2024

National Institutes of Health2020–2020

University of Minnesota2021–2021

Top Works

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

Masatoshi Kudo,Richard S. Finn,et al.

20185,313 citations

Liver Disease Diagnosis and Treatment

Colorectal Cancer Treatments and Studies

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial

Andrew X. Zhu,Richard S. Finn,et al.

20182,498 citations

Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study

Ghassan K. Abou‐Alfa,Vaibhav Sahai,et al.

20201,536 citations

Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

Florian Lordick,Fátima Carneiro,et al.

20221,262 citations

NASH limits anti-tumour surveillance in immunotherapy-treated HCC

Dominik Pfister,Nicolás Gonzalo Núñez,et al.

20211,188 citations

Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Arndt Vogel,Andrés Cervantes,et al.

20181,048 citations

Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial

Robin Kate Kelley,Makoto Ueno,et al.

2023943 citations

Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study

Shukui Qin,Stephen L. Chan,et al.

2023619 citations

Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

Radka Obermannová,María Alsina,et al.

2022602 citations